MD Anderson’s Lauren Averett Byers receives TAMEST O’Donnell Award for seminal contributions to lung cancer research
Lauren Averett Byers, M.D., professor of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center, has received the 2025 Edith and Peter O’Donnell Award in Medicine from the Texas Academy of Medicine, Engineering, Science and Technology (TAMEST). The award recognizes her fundamental discoveries and contributions to identifying novel therapeutic strategies for small cell lung cancer (SCLC), which...
MD Anderson and AmMax Bio announce agreements to advance development of AMB-066 in colorectal cancer patients with minimal residual disease
The University of Texas MD Anderson Cancer Center and AmMax Bio, Inc. today announced a worldwide exclusive license agreement and clinical...
ASH: Triplet combination regimens demonstrate high response rates in multiple leukemias
ABSTRACTS: 216, 219, 1011
SAN DIEGO ― Three clinical trials led by researchers from The University of Texas MD Anderson...
ASH: Monoclonal antibody therapy improves survival in cancer-associated hyper-inflammatory disorder
ABSTRACT: 805
SAN DIEGO – Adult patients with newly diagnosed malignancy-associated hemophagocytic lymphohistiocytosis (mHLH) – a rare, aggressive hyperinflammatory condition – who were treated with the first-in-class monoclonal antibody, ELA026, experienced a 100% response rate and an improved survival rate at two months, according to researchers from The University of Texas MD Anderson Cancer Center.
Data from the Phase...
MD Anderson Research Highlights: ASH 2024 Special Edition
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention...